{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:16:40Z","timestamp":1789402600515,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High intra-patient variability (IPV) of tacrolimus trough concentrations is increasingly recognized as a predictor of poor long-term outcomes in kidney transplant. However, there is a lack of information regarding the association between tacrolimus IPV and graft outcomes according to immunological risk. We analyzed tacrolimus IPV using the coefficient of variability from months 6\u201312 after transplantation in 1080 kidney transplant recipients. Patients were divided into two immunological risk groups based on pre-transplant panel reactive antibodies and donor-specific antibodies. High immunological risk was defined as panel reactive antibodies\u2009\u2265\u200920% or the presence of donor-specific antibodies. The effects of tacrolimus IPV on graft outcomes were significantly different between low and high immunological risk patients. A multivariable Cox regression model confirmed that high tacrolimus IPV was an independent risk factor for graft failure in the high risk group (HR, 2.90; 95% CI, 1.42\u20135.95, <jats:italic>P<\/jats:italic>\u2009=\u20090.004). In the high risk group, high tacrolimus IPV was also significantly associated with increased risk of antibody-mediated rejection (<jats:italic>P<\/jats:italic>\u2009=\u20090.006). In contrast, death-censored graft survival and antibody-mediated rejection in the low immunological risk group was not significantly different by tacrolimus IPV. High tacrolimus IPV significantly increases the risk of graft failure and antibody-mediated rejection in patients with high immunological risk.<\/jats:p>","DOI":"10.1038\/s41598-021-91630-4","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T10:16:45Z","timestamp":1623233805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Clinical significance of tacrolimus intra-patient variability on kidney transplant outcomes according to pre-transplant immunological risk"],"prefix":"10.1038","volume":"11","author":[{"given":"Eun Jin","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Ha","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myoung Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Seun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"key":"91630_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/ajt.15672","volume":"20 Suppl s1","author":"A Hart","year":"2020","unstructured":"Hart, A. et al. OPTN\/SRTR 2018 annual data report: kidney. Am. J. Transpl. 20 Suppl s1, 20\u2013130 (2020).","journal-title":"Am. J. Transpl."},{"key":"91630_CR2","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1111\/j.1600-6143.2011.03539.x","volume":"11","author":"SA Lodhi","year":"2011","unstructured":"Lodhi, S. A., Lamb, K. E. & Meier-Kriesche, H. U. Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success. Am. J. Transpl. 11, 1226\u20131235 (2011).","journal-title":"Am. J. Transpl."},{"key":"91630_CR3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1600-6143.2008.02519.x","volume":"9","author":"ZM El-Zoghby","year":"2009","unstructured":"El-Zoghby, Z. M. et al. Identifying specific causes of kidney allograft loss. Am. J. Transpl. 9, 527\u2013535 (2009).","journal-title":"Am. J. Transpl."},{"key":"91630_CR4","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","volume":"12","author":"J Sellar\u00e9s","year":"2012","unstructured":"Sellar\u00e9s, J. et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am. J. Transpl. 12, 388\u2013399 (2012).","journal-title":"Am. J. Transpl."},{"key":"91630_CR5","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/S0140-6736(17)31283-7","volume":"389","author":"T Wekerle","year":"2017","unstructured":"Wekerle, T., Segev, D., Lechler, R. & Oberbauer, R. Strategies for long-term preservation of kidney graft function. Lancet 389, 2152\u20132162 (2017).","journal-title":"Lancet"},{"key":"91630_CR6","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/ajt.13582","volume":"16","author":"MD Stegall","year":"2016","unstructured":"Stegall, M. D., Morris, R. E., Alloway, R. R. & Mannon, R. B. Developing new immunosuppression for the next generation of transplant recipients: the path forward. Am. J. Transpl. 16, 1094\u20131101 (2016).","journal-title":"Am. J. Transpl."},{"key":"91630_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.trre.2016.10.006","volume":"31","author":"MA Lim","year":"2017","unstructured":"Lim, M. A., Kohli, J. & Bloom, R. D. Immunosuppression for kidney transplantation: Where are we now and where are we going?. Transpl. Rev. (Orlando) 31, 10\u201317 (2017).","journal-title":"Transpl. Rev. (Orlando)"},{"key":"91630_CR8","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1097\/TP.0000000000001648","volume":"101","author":"PJ O\u2019Connell","year":"2017","unstructured":"O\u2019Connell, P. J. et al. Clinical trials for immunosuppression in transplantation: the case for reform and change in direction. Transplantation 101, 1527\u20131534 (2017).","journal-title":"Transplantation"},{"key":"91630_CR9","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1111\/ajt.13758","volume":"16","author":"DA Axelrod","year":"2016","unstructured":"Axelrod, D. A. et al. National variation in use of immunosuppression for kidney transplantation: a call for evidence-based regimen selection. Am. J. Transpl. 16, 2453\u20132462 (2016).","journal-title":"Am. J. Transpl."},{"key":"91630_CR10","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1056\/NEJMoa067411","volume":"357","author":"H Ekberg","year":"2007","unstructured":"Ekberg, H. et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl. J. Med. 357, 2562\u20132575 (2007).","journal-title":"N. Engl. J. Med."},{"key":"91630_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet, M. et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther. Drug. Monit. 41, 261\u2013307 (2019).","journal-title":"Ther. Drug. Monit."},{"key":"91630_CR12","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1097\/TP.0000000000001040","volume":"100","author":"E Rodrigo","year":"2016","unstructured":"Rodrigo, E. et al. Within-patient variability in tacrolimus blood levels predicts kidney graft loss and donor-specific antibody development. Transplantation 100, 2479\u20132485 (2016).","journal-title":"Transplantation"},{"key":"91630_CR13","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1093\/ndt\/gfq096","volume":"25","author":"LC Borra","year":"2010","unstructured":"Borra, L. C. et al. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol. Dial. Transpl. 25, 2757\u20132763 (2010).","journal-title":"Nephrol. Dial. Transpl."},{"key":"91630_CR14","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1111\/ajt.16002","volume":"20","author":"HM Gonzales","year":"2020","unstructured":"Gonzales, H. M. et al. A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation. Am. J. Transpl. 20, 1969\u20131983 (2020).","journal-title":"Am. J. Transpl."},{"key":"91630_CR15","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1681\/ASN.2017030287","volume":"28","author":"C Wiebe","year":"2017","unstructured":"Wiebe, C. et al. Class II eplet mismatch modulates tacrolimus trough levels required to prevent donor-specific antibody development. J. Am. Soc. Nephrol. 28, 3353\u20133362 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"91630_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.trre.2016.02.002","volume":"30","author":"J Pratschke","year":"2016","unstructured":"Pratschke, J. et al. Immunological risk assessment: the key to individualized immunosuppression after kidney transplantation. Transpl. Rev. (Orlando) 30, 77\u201384 (2016).","journal-title":"Transpl. Rev. (Orlando)"},{"key":"91630_CR17","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1093\/ndt\/gfx365","volume":"33","author":"D Abramowicz","year":"2018","unstructured":"Abramowicz, D. et al. Recent advances in kidney transplantation: a viewpoint from the Descartes advisory board. Nephrol. Dial. Transpl. 33, 1699\u20131707 (2018).","journal-title":"Nephrol. Dial. Transpl."},{"key":"91630_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/cpt.1618","volume":"107","author":"DRJ Kuypers","year":"2020","unstructured":"Kuypers, D. R. J. Intrapatient variability of tacrolimus exposure in solid organ transplantation: a novel marker for clinical outcome. Clin. Pharmacol. Ther. 107, 347\u2013358 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"key":"91630_CR19","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/ajt.14504","volume":"18","author":"S Davis","year":"2018","unstructured":"Davis, S. et al. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. Am. J. Transpl. 18, 907\u2013915 (2018).","journal-title":"Am. J. Transpl."},{"key":"91630_CR20","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1097\/TP.0000000000000149","volume":"97","author":"KR Richards","year":"2014","unstructured":"Richards, K. R. et al. Tacrolimus trough level at discharge predicts acute rejection in moderately sensitized renal transplant recipients. Transplantation 97, 986\u2013991 (2014).","journal-title":"Transplantation"},{"key":"91630_CR21","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1111\/ajt.14752","volume":"18","author":"AR Tambur","year":"2018","unstructured":"Tambur, A. R. et al. Sensitization in transplantation: assessment of risk (STAR) 2017 working group meeting report. Am. J. Transpl. 18, 1604\u20131614 (2018).","journal-title":"Am. J. Transpl."},{"key":"91630_CR22","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1302506","volume":"369","author":"A Loupy","year":"2013","unstructured":"Loupy, A. et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N. Engl. J. Med. 369, 1215\u20131226 (2013).","journal-title":"N. Engl. J. Med."},{"key":"91630_CR23","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1056\/NEJMoa035717","volume":"352","author":"D Dragun","year":"2005","unstructured":"Dragun, D. et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N. Engl. J. Med. 352, 558\u2013569 (2005).","journal-title":"N. Engl. J. Med."},{"key":"91630_CR24","first-page":"1244","volume":"32","author":"J Lee","year":"2017","unstructured":"Lee, J. et al. The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation. Nephrol. Dial. Transpl. 32, 1244\u20131250 (2017).","journal-title":"Nephrol. Dial. Transpl."},{"key":"91630_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00228-013-1584-7","volume":"70","author":"E St\u00f8rset","year":"2014","unstructured":"St\u00f8rset, E. et al. Importance of hematocrit for a tacrolimus target concentration strategy. Eur. J. Clin. Pharmacol. 70, 65\u201377 (2014).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"91630_CR26","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1111\/ajt.15199","volume":"19","author":"AD Leino","year":"2019","unstructured":"Leino, A. D. et al. Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values. Am. J. Transpl. 19, 1410\u20131420 (2019).","journal-title":"Am. J. Transpl."},{"key":"91630_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/TP.0b013e3182725532","volume":"95","author":"DR Kuypers","year":"2013","unstructured":"Kuypers, D. R. et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation 95, 333\u2013340 (2013).","journal-title":"Transplantation"},{"key":"91630_CR28","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/ndt\/gfw455","volume":"32","author":"J Lee","year":"2017","unstructured":"Lee, J. et al. Rituximab and hepatitis B reactivation in HBsAg-negative\/ anti-HBc-positive kidney transplant recipients. Nephrol. Dial. Transpl. 32, 722\u2013729 (2017).","journal-title":"Nephrol. Dial. Transpl."},{"key":"91630_CR29","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604\u2013612 (2009).","journal-title":"Ann. Intern. Med."},{"key":"91630_CR30","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/ajt.14625","volume":"18","author":"M Haas","year":"2018","unstructured":"Haas, M. et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am. J. Transpl. 18, 293\u2013307 (2018).","journal-title":"Am. J. Transpl."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91630-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91630-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91630-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T09:36:23Z","timestamp":1670060183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91630-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["91630"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-91630-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,9]]},"assertion":[{"value":"7 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12114"}}